'A precedent you might not want to set.' FDA-invited expert blasts Moderna unblinding plan as adcomm gets underway
At last week’s advisory committee, Pfizer executives shot down a proposal from a Stanford expert on how to keep a blinded study going even after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
